

Don S Dizon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/737660/publications.pdf>

Version: 2024-02-01

212
papers

7,130
citations

50276

46
h-index

69250

77
g-index

216
all docs

216
docs citations

216
times ranked

9693
citing authors

#	ARTICLE	IF	CITATIONS
1	Social Media and Oncology: The Time Is Now. JCO Oncology Practice, 2022, 18, 525-527.	2.9	4
2	Analysis of Hematology and Oncology Fellowship Website Content and Diversity Representation. JCO Oncology Practice, 2022, , OP2100623.	2.9	4
3	eSyM: An Electronic Health Recordâ€“Integrated Patient-Reported Outcomesâ€“Based Cancer Symptom Management Program Used by Six Diverse Health Systems. JCO Clinical Cancer Informatics, 2022, 6, e2100137.	2.1	19
4	Netiquette for social media engagement for oncology professionals. Future Oncology, 2022, 18, 1133-1141.	2.4	3
5	Ethics-Centered Guidelines for Social Media Use by Oncology Professionals: A Call to Action. JCO Oncology Practice, 2022, 18, 537-540.	2.9	2
6	Using Social Media for Clinical Research: Recommendations and Examples From the Brown-Lifespan Center for Digital Health. Journal of Medical Internet Research, 2022, 24, e35804.	4.3	2
7	Implementation of patient-reported outcomes for symptom management in oncology practice through the SIMPRO research consortium: a protocol for a pragmatic type II hybrid effectiveness-implementation multi-center cluster-randomized stepped wedge trial. Trials, 2022, 23, .	1.6	9
8	The (R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage. Cancer Discovery, 2022, 12, 1620-1624.	9.4	9
9	Social Media and the Quest for Equity and Diversity in Oncology: On Safe Spaces and the Concept of the Public Physician. JCO Oncology Practice, 2022, 18, 572-577.	2.9	1
10	Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. American Journal of Transplantation, 2021, 21, 460-474.	4.7	67
11	â€œGoing Flatâ€“After Mastectomy: Patient-Reported Outcomes by Online Survey. Annals of Surgical Oncology, 2021, 28, 2493-2505.	1.5	28
12	Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer. Breast Cancer Research and Treatment, 2021, 186, 667-676.	2.5	5
13	Abstract PS7-57: Patient risk factors for loss to breast oncologic follow up. , 2021, , .		0
14	Identification of Transgender People With Cancer in Electronic Health Records: Recommendations Based on CancerLinQ Observations. JCO Oncology Practice, 2021, 17, e336-e342.	2.9	7
15	People with cancer are likely to accept the COVID-19 vaccine, but politics tracks with attitudes: An inspire and COSMO survey.. Journal of Clinical Oncology, 2021, 39, 1531-1531.	1.6	11
16	Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results. Cancers, 2021, 13, 3196.	3.7	3
17	Impact of the COVID-19 Pandemic on Oncologist Burnout, Emotional Well-Being, and Moral Distress: Considerations for the Cancer Organizationâ€™s Response for Readiness, Mitigation, and Resilience. JCO Oncology Practice, 2021, 17, 365-374.	2.9	53
18	Sporadic uterine Lymphangi leiomyomatosis (LAM): Report of a unique case arising in the lower uterine segment with short review. Gynecologic Oncology Reports, 2021, 37, 100812.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Sexual Function, Quality of Life, and Mood After Radiation Therapy in Patients with Anal Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 204-210.	1.3	20
20	New Cardiac Abnormalities After Radiotherapy in Breast Cancer Patients Treated With Trastuzumab. <i>Clinical Breast Cancer</i> , 2020, 20, 246-252.	2.4	6
21	Phase II study of aximogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2020, 158, 562-569.	1.4	35
22	Waging War on War Metaphors in Cancer and COVID-19. <i>JCO Oncology Practice</i> , 2020, 16, 624-627.	2.9	21
23	Clinical Trials in the Era of Digital Engagement: A SWOG Call to Action. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 254-258.	2.1	5
24	Now, More Than Ever, Is the Time for Early and Frequent Advance Care Planning. <i>Journal of Clinical Oncology</i> , 2020, 38, 2956-2959.	1.6	9
25	A social media survey of women who do not pursue reconstruction after mastectomy for breast cancer: Characterizing the "Going Flat" movement. <i>Breast Journal</i> , 2020, 26, 1455-1457.	1.0	14
26	Sexual Health Issues in Cancer Survivors. <i>Seminars in Oncology Nursing</i> , 2020, 36, 150981.	1.5	8
27	Investigator Use of Social Media for Recruitment of Patients for Cancer Clinical Trials. <i>JAMA Network Open</i> , 2020, 3, e2031202.	5.9	10
28	Genomic landscape of angiosarcoma: A targeted and immunotherapy biomarker analysis of 143 patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11545-11545.	1.6	1
29	Endometrial Cancer Genetic Classification and Its Clinical Application. , 2020, , 23-47.		0
30	Does age contribute to distress in new geriatric oncology patients?. <i>Journal of Clinical Oncology</i> , 2020, 38, e24023-e24023.	1.6	0
31	Appropriateness of opioid prescribing in cancer patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, e24129-e24129.	1.6	0
32	Identification of transgender people with cancer in electronic health records (EHR): Recommendations based on CancerLinQ observations.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19046-e19046.	1.6	0
33	Distress: Characterizing What Causes the Thermometer to Shift in Patients with Newly Diagnosed Breast Cancer Attending a Multidisciplinary Clinic. <i>Annals of Surgical Oncology</i> , 2019, 26, 3204-3209.	1.5	7
34	Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer. <i>JAMA Oncology</i> , 2019, 5, 1731.	7.1	150
35	Physician Perceptions of the Use of Social Media for Recruitment of Patients in Cancer Clinical Trials. <i>JAMA Network Open</i> , 2019, 2, e1911528.	5.9	21
36	Organizing Online Health Content: Developing Hashtag Collections for Healthier Internet-Based People and Communities. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-10.	2.1	23

#	ARTICLE	IF	CITATIONS
37	Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of MÃ¼llerian origin. <i>Gynecologic Oncology</i> , 2019, 153, 223-229.	1.4	7
38	Protecting Patient Privacy in Narratives: The Lifespan-Brown Checklist for Appropriate Use of Patient Narratives. <i>Oncologist</i> , 2019, 24, 285-287.	3.7	1
39	Prostate Cancer Social Media: In YouTube We Trust?. <i>European Urology</i> , 2019, 75, 568-569.	1.9	18
40	Desire to address costs at time of treatment decisions among patients with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6640-6640.	1.6	2
41	The individualized Goals of Care Discussion Guide: A simple tool to empower patients with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11622-11622.	1.6	0
42	After cancer, whatâ€™s more important? The survivorship care plan or the survivorship care visit?. <i>Journal of Clinical Oncology</i> , 2019, 37, 11618-11618.	1.6	0
43	Is Hormone Replacement Therapy Safe in Women With a BRCA Mutation?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 313-315.	1.3	30
44	Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair-Deficient Endometrial Cancer and a Germline <i>BRCA1</i> Mutation. <i>Oncologist</i> , 2018, 23, 650-653.	3.7	8
45	Clinical needs assessment for sexual health among cancer patients receiving pelvic radiation: Implications for development of a radiation oncology sexual health clinic. <i>Practical Radiation Oncology</i> , 2018, 8, 206-212.	2.1	3
46	Pilot study of a multimodal intervention to enhance sexual function in survivors of hematopoietic stem cell transplantation. <i>Cancer</i> , 2018, 124, 2438-2446.	4.1	28
47	Axillary Ultrasound Fine Needle Aspiration Biopsy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 702-707.	1.3	4
48	A Multimodal Intervention Enhances Sexual Function and Quality of Life (QOL) in Hematopoietic Stem Cell Transplant (HCT) Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S252.	2.0	0
49	Palliative Total Pelvic Exenteration for Gynecologic Cancers: A Cross-sectional Study of Society of Gynecologic Oncology Members. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1796-1804.	2.5	6
50	Incorporating Digital Tools to Improve Clinical Trial Infrastructure: A White Paper From the Digital Engagement Committee of SWOG. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-8.	2.1	7
51	Sexuality, fertility and pregnancy following breast cancer treatment. <i>Gland Surgery</i> , 2018, 7, 404-410.	1.1	12
52	Survivorship care planning in gynecologic oncologyâ€™ perspectives from patients, caregivers, and health care providers. <i>Journal of Cancer Survivorship</i> , 2018, 12, 762-774.	2.9	19
53	A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2018, 151, 202-207.	1.4	10
54	A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. <i>Gynecologic Oncology</i> , 2018, 150, 274-281.	1.4	105

#	ARTICLE	IF	CITATIONS
55	Cluster Analysis Demonstrates the Need to Individualize Care for Cancer Survivors. <i>Oncologist</i> , 2018, 23, 1474-1481.	3.7	13
56	The Needs of Women Treated for Ovarian Cancer: Results From a #gynccsm Twitter Chat. <i>Journal of Patient-centered Research and Reviews</i> , 2018, 5, 149-157.	0.9	15
57	Cluster analysis to demonstrate the need to individualize care for cancer survivors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 62-62.	1.6	0
58	Survivorship care planning in gynecologic oncology: Perspectives from patients, caregivers, and health care providers.. <i>Journal of Clinical Oncology</i> , 2018, 36, 63-63.	1.6	2
59	Considering cost and value with patients in clinic.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18905-e18905.	1.6	0
60	Identifying sexual orientation in the medical record: A first step towards understanding gynecologic cancer disparities.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18641-e18641.	1.6	0
61	Advance care planning as a shared endeavor: completion of ACP documents in a multidisciplinary cancer program. <i>Psycho-Oncology</i> , 2017, 26, 67-73.	2.3	21
62	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2017, 35, 1341-1367.	1.6	318
63	Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 92-120.	4.9	136
64	The emerging role of professional social media use in oncology. <i>Future Oncology</i> , 2017, 13, 1281-1285.	2.4	32
65	A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 145, 236-242.	1.4	17
66	A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852). <i>Annals of Oncology</i> , 2017, 28, 505-511.	1.2	57
67	A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 144, 101-106.	1.4	7
68	Neoadjuvant chemotherapy for newly diagnosed ovarian cancer: It's all about selection. <i>Gynecologic Oncology</i> , 2017, 144, 241-242.	1.4	6
69	What's the Harm?. <i>Oncologist</i> , 2017, 22, 1006-1007.	3.7	2
70	PARP inhibitors for targeted treatment in ovarian cancer. <i>Lancet, The</i> , 2017, 390, 1929-1930.	18.7	30
71	Twitter 101 and beyond: introduction to social media platforms available to practicing hematologist/oncologists. <i>Seminars in Hematology</i> , 2017, 54, 177-183.	3.4	13
72	Risks and benefits of Twitter use by hematologists/oncologists in the era of digital medicine. <i>Seminars in Hematology</i> , 2017, 54, 198-204.	3.4	29

#	ARTICLE	IF	CITATIONS
73	Breast-Specific Sensuality and Sexual Function in Cancer Survivorship: Does Surgical Modality Matter?. <i>Annals of Surgical Oncology</i> , 2017, 24, 3133-3140.	1.5	40
74	Extended carboplatin infusion does not reduce frequency of hypersensitivity reaction at initiation of retreatment in patients with recurrent platinum-sensitive ovarian cancer. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 177-178.	3.8	14
75	Reply to the letter to the editor "Integrating communication as a core skill in the global curriculum for medical oncology" by Horlait et al.. <i>Annals of Oncology</i> , 2017, 28, 905-906.	1.2	1
76	Phase 2, two-group, two-stage, open-label study of avelumab in patients with microsatellite stable, microsatellite instable and <i>POLE</i> -mutated recurrent or persistent endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5615-TPS5615.	1.6	6
77	A multimodal intervention to enhance sexual function and quality of life (QOL) in hematopoietic stem cell transplant (HCT) survivors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10013-10013.	1.6	0
78	A multimodal intervention to enhance sexual function and quality of life (QOL) in hematopoietic stem cell transplant (HCT) survivors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 191-191.	1.6	0
79	Cervical cancer control in Latin America: A call to action. <i>Cancer</i> , 2016, 122, 502-514.	4.1	32
80	Breast Cancer Risk Assessment. <i>Obstetrical and Gynecological Survey</i> , 2016, 71, 156-157.	0.4	0
81	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016, 1, e000097.	4.5	82
82	Social media in cancer care: highlights, challenges & opportunities. <i>Future Oncology</i> , 2016, 12, 1549-1552.	2.4	40
83	Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 3460-3473.	1.6	318
84	Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. <i>Gynecologic Oncology</i> , 2016, 143, 3-15.	1.4	208
85	Systemic Therapies for Nonmetastatic Breast Cancer: The Role of Neoadjuvant and Adjuvant Chemotherapy and the Use of Endocrine Therapy. <i>Clinical Obstetrics and Gynecology</i> , 2016, 59, 756-771.	1.1	2
86	Communication About Sexuality in Advanced Illness Aligns With a Palliative Care Approach to Patient-Centered Care. <i>Current Oncology Reports</i> , 2016, 18, 11.	4.0	23
87	Sexuality After Cancer: A Model for Male Survivors. <i>Journal of Sexual Medicine</i> , 2016, 13, 70-78.	0.6	32
88	Breast Cancer Risk Assessment: Moving Beyond BRCA 1 and 2. <i>Seminars in Radiation Oncology</i> , 2016, 26, 3-8.	2.2	20
89	A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer. <i>Gynecologic Oncology</i> , 2016, 141, 108-112.	1.4	6
90	Chemotherapy in ovarian germ cell tumors: A systematic review. <i>Gynecologic Oncology</i> , 2016, 141, 602-607.	1.4	24

#	ARTICLE	IF	CITATIONS
91	Disease-Specific Hashtags for Online Communication About Cancer Care. <i>JAMA Oncology</i> , 2016, 2, 392.	7.1	91
92	Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2016, 34, 987-1011.	1.6	141
93	ADX51001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: Results from stage I of the phase II GOG/NCIC125 study. <i>Journal of Clinical Oncology</i> , 2016, 34, 5516-5516.	1.6	19
94	Global Cancer Institute (GCI) multi-disciplinary tumor boards (MTBs) as an educational tool to improve guideline-based cancer clinical practice in low- and middle-income countries (LMICs). <i>Journal of Clinical Oncology</i> , 2016, 34, e18007-e18007.	1.6	0
95	A description of a small cohort of Argentinian women presenting with cervical cancer (CC) highlighting the need for CC control in Latin America (LA). <i>Journal of Clinical Oncology</i> , 2016, 34, e17026-e17026.	1.6	0
96	A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus: An NRG/Gynecologic Oncology Group study. <i>Journal of Clinical Oncology</i> , 2016, 34, 5585-5585.	1.6	0
97	Uterine Sarcoma, Version 1.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1321-1331.	4.9	58
98	Development of a Breast Cancer Advocacy and Access Health Program in Nicaragua. <i>Breast Journal</i> , 2015, 21, 570-571.	1.0	1
99	Advances in the Management of Recurrent Endometrial Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 206-212.	1.3	74
100	Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. <i>Gynecologic Oncology</i> , 2015, 138, 18-23.	1.4	64
101	Making a Difference: Distinguishing Two Primaries From Metastasis in Synchronous Tumors of the Ovary and Uterus. <i>Journal of the National Cancer Institute</i> , 2015, 108, djv442.	6.3	13
102	Delay in chemotherapy administration adversely affects overall survival in elderly ovarian cancer patients. <i>Gynecologic Oncology</i> , 2015, 136, 403.	1.4	0
103	Clinical Cancer Advances 2015: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2015, 33, 786-809.	1.6	102
104	Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2015, 21, 2305-2314.	7.0	85
105	Delay in chemotherapy administration impacts survival in elderly patients with epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 137, 401-405.	1.4	51
106	Sexual Recovery After Cancer. <i>Current Sexual Health Reports</i> , 2015, 7, 63-69.	0.8	1
107	Toward Eubiosia: Bridging Oncology and Palliative Care. <i>Oncologist</i> , 2015, 20, 5-6.	3.7	1
108	Progress and remaining challenges for cancer control in Latin America and the Caribbean. <i>Lancet Oncology</i> , 2015, 16, 1405-1438.	10.7	142

#	ARTICLE	IF	CITATIONS
109	A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P.. Journal of Clinical Oncology, 2015, 33, 5500-5500.	1.6	34
110	Disease-specific hashtags for online communication about cancer care.. Journal of Clinical Oncology, 2015, 33, 6520-6520.	1.6	6
111	Breast cancer and sexual function. Translational Andrology and Urology, 2015, 4, 160-8.	1.4	39
112	Results of a phase I pharmacokinetic study of intraperitoneal bortezomib (B) and carboplatin (C) in patients with persistent or recurrent ovarian cancer (OC): An NRG/Gynecologic Oncology Group study.. Journal of Clinical Oncology, 2015, 33, 5515-5515.	1.6	0
113	Survivorship in Gynecologic Cancer: Enduring the Treatment toward a New Normal. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e288-e294.	3.8	4
114	Improving quality of life in female cancer survivors: current status and future questions. Future Oncology, 2014, 10, 1015-1026.	2.4	4
115	A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: An NRG Oncology/Gynecologic Oncology Group Study. Gynecologic Oncology, 2014, 135, 44-48.	1.4	16
116	Management and outcomes for elderly women with vulvar cancer over time. BJOG: an International Journal of Obstetrics and Gynaecology, 2014, 121, 719-727.	2.3	25
117	A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecologic Oncology, 2014, 135, 441-445.	1.4	69
118	Sexual Health as a Survivorship Issue for Female Cancer Survivors. Oncologist, 2014, 19, 202-210.	3.7	99
119	Narratives in Oncology. Oncologist, 2014, 19, 789-789.	3.7	0
120	Sexual Dysfunction in Female Cancer Survivors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 101-106.	1.3	70
121	My Father's Final Lesson. Oncologist, 2014, 19, 1110-1111.	3.7	0
122	Guilt and the Burden on Oncology Providers. Oncologist, 2014, 19, 441-442.	3.7	1
123	State of the science in cervical cancer: Where we are today and where we need to go. Cancer, 2014, 120, 2282-2288.	4.1	36
124	Cervical Cancer Prevention: Asian-American Women's Knowledge and Participation in Screening Practices. Women's Health Issues, 2014, 24, e231-e236.	2.0	18
125	Precision medicine and personalized breast cancer: combination pertuzumab therapy. Pharmacogenomics and Personalized Medicine, 2014, 7, 95.	0.7	13
126	Survivorship: Nutrition and Weight Management, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1396-1406.	4.9	31

#	ARTICLE	IF	CITATIONS
127	Survivorship: Immunizations and Prevention of Infections, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1098-1111.	4.9	16
128	Survivorship: Healthy Lifestyles, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1222-1237.	4.9	47
129	Survivorship: Screening for Cancer and Treatment Effects, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1526-1531.	4.9	14
130	A phase 2 study of live-attenuated listeria monocytogenes cancer immunotherapy (ADXS11-001) in the treatment of persistent or recurrent cancer of the cervix (GOG-0265).. Journal of Clinical Oncology, 2014, 32, TPS5617-TPS5617.	1.6	5
131	Long-term follow up for a phase I trial HER2/neu-targeted T cells in women with advanced breast cancer.. Journal of Clinical Oncology, 2014, 32, 3075-3075.	1.6	1
132	Advances in the diagnosis and treatment of uterine sarcomas. Discovery Medicine, 2014, 17, 339-45.	0.5	9
133	Why DOMA is unconstitutional, beyond the traditional views of same sex relationships. Journal of Assisted Reproduction and Genetics, 2013, 30, 861-861.	2.5	0
134	The effects of age on treatment and outcomes in women with stages IB1â€“IIB cervical cancer. Journal of Geriatric Oncology, 2013, 4, 374-381.	1.0	4
135	Outcomes for Women Receiving Bevacizumab forÂTreatment of Ovarian Cancer Versus Other Solid Tumors at an Academic Oncology Center. Clinical Ovarian and Other Gynecologic Cancer, 2013, 6, 21-24.	0.1	1
136	Pushing the bar in treatment of cervical cancer: What can comprehensive cancer centers do on their own?. Gynecologic Oncology, 2013, 131, 464-466.	1.4	2
137	Sexual dysfunction in women with cancer. Fertility and Sterility, 2013, 100, 916-921.	1.0	73
138	Randomised controlled trial comparing hypnotherapy versus gabapentin for the treatment of hot flashes in breast cancer survivors: a pilot study. BMJ Open, 2013, 3, e003138.	1.9	27
139	Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53. Obstetrics and Gynecology International, 2013, 2013, 1-10.	1.3	25
140	Importance of clarifying patients' desired role in shared decision making to match their level of engagement with their preferences. BMJ, The, 2013, 347, f7066-f7066.	6.0	94
141	Where do Antiangiogenic Agents Belong in the Treatment Algorithm for Ovarian Cancer?. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 519-525.	1.3	2
142	Clear cell cancer of the ovary. Current Opinion in Oncology, 2013, 25, 553-557.	2.4	14
143	Locally Advanced Vulvar Cancer in Elderly Women. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 279-282.	1.3	7
144	Patterns of Recurrence in Patients Treated With Bevacizumab in the Primary Treatment of Advanced Epithelial Ovarian Cancer. International Journal of Gynecological Cancer, 2013, 23, 1219-1225.	2.5	18

#	ARTICLE	IF	CITATIONS
145	Preparing for Survivorship: Quality of Life in Breast Cancer Survivors. <i>Journal of Sexual Medicine</i> , 2013, 10, 16-20.	0.6	14
146	Is Tumor Board Relevant?. <i>Breast Journal</i> , 2013, 19, 351-353.	1.0	4
147	The Power of Words: Discussing Decision Making and Prognosis. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 442-446.	3.8	7
148	Effect of female-dominant support networks on end-of-life decision making among women with advanced or recurrent cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 6590-6590.	1.6	0
149	Achieving quality: Comparing recommendations for cancer care between NCCN and ESMO.. <i>Journal of Clinical Oncology</i> , 2013, 31, 6579-6579.	1.6	0
150	The role of oncologic health care providers in end of life discussions for women with recurrent gynecologic or breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e20543-e20543.	1.6	0
151	Practical Guidance: The Use of Social Media In Oncology Practice. <i>Journal of Oncology Practice</i> , 2012, 8, e114-e124.	2.5	140
152	Phase II Activity of Belinostat (PXD-101), Carboplatin, and Paclitaxel in Women With Previously Treated Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 979-986.	2.5	78
153	Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. <i>Gynecologic Oncology</i> , 2012, 127, 141-146.	1.4	80
154	Medical Therapy of Endometrial Cancer. <i>Drugs</i> , 2012, 72, 705-713.	10.9	36
155	Antimitotic Inhibitors. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 607-628.	2.2	14
156	Novel Antiangiogenic Therapies in Ovarian Cancer. <i>Women's Health</i> , 2012, 8, 447-453.	1.5	3
157	Feels good, looks better: Proportion of women completing all stages of breast reconstruction after mastectomy for breast cancer treatment or prophylaxis. <i>Gynecologic Oncology</i> , 2012, 125, S47-S48.	1.4	0
158	A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2012, 125, 367-371.	1.4	90
159	The effects of age on treatment and outcomes in women with stage IB-IIb cervical cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5100-5100.	1.6	0
160	Breast Cancer. <i>Clinical Obstetrics and Gynecology</i> , 2011, 54, 150-156.	1.1	5
161	Placental Mesenchymal Dysplasia Presenting as a Twin Gestation With Complete Molar Pregnancy. <i>Obstetrics and Gynecology</i> , 2011, 118, 445-449.	2.4	22
162	Communicating uncertainty can lead to less decision satisfaction: a necessary cost of involving patients in shared decision making?. <i>Health Expectations</i> , 2011, 14, 84-91.	2.6	140

#	ARTICLE	IF	CITATIONS
163	Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2011, 123, 182-186.	1.4	15
164	Patterns of Cellular Distribution with the Sentinel Node Positive for Breast Cancer. <i>International Journal of Breast Cancer</i> , 2011, 2011, 1-4.	1.2	0
165	New advances in the treatment of endometrial cancer. <i>Clinical Investigation</i> , 2011, 1, 413-422.	0.0	1
166	Evaluation of the Female with Sexual Dysfunction. , 2011, , 351-356.		0
167	Addressing clinical trials: Can the Multidisciplinary Tumor Board improve participation? A study from an academic women's cancer program. <i>Gynecologic Oncology</i> , 2010, 116, 295-300.	1.4	36
168	Treatment options for advanced endometrial carcinoma. <i>Gynecologic Oncology</i> , 2010, 117, 373-381.	1.4	77
169	Clinical Characteristics and Choices Regarding Risk-Reducing Surgery in BRCA Mutation Carriers. <i>Gynecologic and Obstetric Investigation</i> , 2010, 69, 270-273.	1.6	18
170	Phase II Study of Carboplatin, Paclitaxel, and Bevacizumab With Maintenance Bevacizumab As First-Line Chemotherapy for Advanced Malignant Ovarian Tumors. <i>Journal of Clinical Oncology</i> , 2010, 28, 154-159.	1.6	96
171	HER-dimerization inhibitors: evaluating pertuzumab in women's cancers. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 243-250.	3.1	13
172	Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1215-1223.	1.6	172
173	Is There a Taxane-Free Interval That Predicts Response to Taxanes as a Later-Line Treatment of Recurrent Ovarian or Primary Peritoneal Cancer?. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 343-347.	2.5	4
174	Advance Care Planning Decisions of Women with Cancer: Provider Recognition and Stability of Choices. <i>Journal of Psychosocial Oncology</i> , 2009, 27, 383-395.	1.2	4
175	Phase II Trial of Ixabepilone As Second-Line Treatment in Advanced Endometrial Cancer: Gynecologic Oncology Group Trial 129-P. <i>Journal of Clinical Oncology</i> , 2009, 27, 3104-3108.	1.6	106
176	New-generation platinum agents for solid tumors. <i>Future Oncology</i> , 2009, 5, 33-42.	2.4	101
177	Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A Brown University Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 4693-4700.	1.6	95
178	Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA) > 2 m ² . <i>Gynecologic Oncology</i> , 2009, 114, 53-56.	1.4	27
179	Quality of Life after Breast Cancer: Survivorship and Sexuality. <i>Breast Journal</i> , 2009, 15, 500-504.	1.0	76
180	Sexual Ramifications of Medical Illness. <i>Clinical Obstetrics and Gynecology</i> , 2009, 52, 691-701.	1.1	7

#	ARTICLE	IF	CITATIONS
181	The Differential Diagnosis of Dyspnea in a Woman with Metastatic Breast Cancer-Consideration Beyond Pulmonary Embolism. <i>Breast Journal</i> , 2008, 14, 90-91.	1.0	2
182	Society of Gynecologic Oncologists Position Paper: Breast Cancer Care. <i>Gynecologic Oncology</i> , 2008, 110, 7-12.	1.4	2
183	Regional Chemotherapy: A Focus on Hepatic Artery Infusion for Colorectal Cancer Liver Metastases. <i>Surgical Oncology Clinics of North America</i> , 2008, 17, 759-771.	1.5	32
184	HER dimerization inhibitors: developing pertuzumab as an anticancer agent in women's oncology. <i>Expert Opinion on Drug Discovery</i> , 2008, 3, 1363-1369.	5.0	1
185	For Women Receiving Chemotherapy for Clinically Apparent Early Ovarian Cancer, Is There a Benefit to Surgical Staging?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 39-42.	1.3	11
186	Oral Thalidomide as Palliative Chemotherapy in Women with Advanced Ovarian Cancer. <i>Journal of Palliative Medicine</i> , 2007, 10, 61-66.	1.1	15
187	Does One Person Provide It All? Primary Support and Advanced Care Planning for Women With Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 1412-1416.	1.6	12
188	Defining social support systems for women with breast cancer. <i>American Journal of Surgery</i> , 2007, 194, 501-503.	1.8	15
189	Clinical characteristics of women presenting with skin-only recurrence of breast cancer. <i>American Journal of Surgery</i> , 2007, 194, 494-496.	1.8	5
190	Sex, Intimacy, and the Gynecologic Oncologist. <i>Journal of Psychosocial Oncology</i> , 2007, 25, 61-70.	1.2	82
191	Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital. <i>Gynecologic Oncology</i> , 2007, 105, 81-83.	1.4	55
192	A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2007, 25, 335-341.	2.6	15
193	Role of ultrasound-guided axillary fine-needle aspiration in the management of invasive breast cancer. <i>American Journal of Surgery</i> , 2006, 192, 458-461.	1.8	34
194	Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program. <i>Gynecologic Oncology</i> , 2006, 100, 149-151.	1.4	39
195	Two for good measure: Six versus eight cycles of carboplatin and paclitaxel as adjuvant treatment for epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 100, 417-421.	1.4	13
196	Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin. <i>Gynecologic Oncology</i> , 2006, 103, 72-74.	1.4	14
197	Phenethyl isothiocyanate (PEITC) inhibits growth of ovarian cancer cells by inducing apoptosis: Role of caspase and MAPK activation. <i>Gynecologic Oncology</i> , 2006, 103, 261-270.	1.4	115
198	Ovarian Cancer Associated with Testosterone Supplementation in a Female-to-Male Transsexual Patient. <i>Gynecologic and Obstetric Investigation</i> , 2006, 62, 226-228.	1.6	81

#	ARTICLE	IF	CITATIONS
199	Phase I Trial of Bortezomib and Carboplatin in Recurrent Ovarian or Primary Peritoneal Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 5943-5949.	1.6	118
200	Dyspnea during Thalidomide Treatment for Advanced Ovarian Cancer. <i>Annals of Pharmacotherapy</i> , 2005, 39, 962-965.	1.9	11
201	Incorporating Targeted Treatments into Standard Regimens: Whither the Role of Established Doses?. <i>Cancer Investigation</i> , 2004, 22, 954-954.	1.3	0
202	Phase II Study of CT-2103 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 4523-4531.	1.6	122
203	Intraperitoneal Cisplatin with Intraperitoneal Gemcitabine in Patients with Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 2962-2967.	7.0	41
204	Chemotherapy-induced dyspareunia: a case study of vaginal mucositis and pegylated liposomal doxorubicin injection in advanced stage ovarian carcinoma. <i>Gynecologic Oncology</i> , 2004, 93, 561-563.	1.4	18
205	Clinicopathologic Analysis of Early-stage Sporadic Ovarian Carcinoma. <i>American Journal of Surgical Pathology</i> , 2004, 28, 147-159.	3.7	77
206	Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. <i>Gynecologic Oncology</i> , 2003, 91, 584-590.	1.4	45
207	The effects of CO2 pneumoperitoneum on the survival of women with persistent metastatic ovarian cancer. <i>Gynecologic Oncology</i> , 2003, 90, 431-434.	1.4	36
208	Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. <i>Gynecologic Oncology</i> , 2003, 91, 123-129.	1.4	43
209	Analysis of Patients with Epithelial Ovarian Cancer or Fallopian Tube Carcinoma Retreated with Cisplatin after the Development of a Carboplatin Allergy. <i>Gynecologic Oncology</i> , 2002, 84, 378-382.	1.4	95
210	Retrospective Analysis of Carboplatin and Paclitaxel as Initial Second-Line Therapy for Recurrent Epithelial Ovarian Carcinoma: Application Toward a Dynamic Disease State Model of Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 1238-1247.	1.6	87
211	Intrahepatic arterial infusion of chemotherapy: Clinical results. <i>Seminars in Oncology</i> , 2002, 29, 126-135.	2.2	32
212	A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. <i>Clinical Cancer Research</i> , 2002, 8, 2505-11.	7.0	339